Phaseline

Targets › PTAFR

PTAFR (Platelet-activating factor receptor): drug programs, companies and trials

1 program from 1 company in 3 trials: 1 Phase 1, 1 Phase 3, 1 Phase 2; Genitourinary, Immunology.

Receptor for platelet activating factor, a chemotactic phospholipid mediator that possesses potent inflammatory, smooth-muscle contractile and hypotensive activity. Seems to mediate its action via a G protein that activates a phosphatidylinositol-calcium second messenger system. (UniProt, P25105)

Open in Phaseline: the race on PTAFR, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Noucor HealthRupatadine
Platelet activating factor receptor antagonist; Histamine H1 receptor antagonist
PTAFR, HRH1Phase 1Renal Impairment; Rheumatoid Arthritis; Ulcerative Colitis–

Conditions

Renal Impairment (1) Rheumatoid Arthritis (1) Ulcerative Colitis (1)

Modalities

small molecule (1)

Companies

Noucor Health (1)

Related targets

HRH1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.